{"id":346,"date":"2025-09-17T12:46:46","date_gmt":"2025-09-17T12:46:46","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=346"},"modified":"2025-09-17T12:47:48","modified_gmt":"2025-09-17T12:47:48","slug":"unannounced-deal-innovent-and-ollin-entered-a-license-for-vegf-ang2-bispecific-antibody-ibi324-oln324","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/346.html","title":{"rendered":"[Unannounced Deal]   Innovent and Ollin entered a License for VEGF\/Ang2 Bispecific Antibody IBI324 (OLN324)"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Asset Name: IBI324 (OLN324)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensor (Seller): Innovent Biologics (China)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensee (Buyer): \u00a0Ollin Biosciences (US) <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Modality: Bispecific antibody (BsAb)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Target: VEGF\/Ang2<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Potential Indication: wet AMD and DME (wet (neovascular) age-related macular degeneration or diabetic macular edema)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Current Stage: Phase I<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Scope of Authority:  Undisclosed.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Payment Detail: Undisclosed.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Link:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/ollin.bio\/press-releases\/ollin-biosciences-launches-with-mission-to-accelerate-best-in-class-therapies-in-ophthalmology\/\">Ollin Biosciences Launches with Mission to Accelerate Best-in-class Therapies in Ophthalmology | Ollin Bio<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Note:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Chinese Name of Innovent Biologics, \u4fe1\u8fbe\u751f\u7269<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Asset Name: IBI324 (OLN324) Licensor (Seller): Innovent Biologics (China) Licensee (Buyer): \u00a0Ollin Biosciences (US) . Asset &hellip; <a title=\"[Unannounced Deal]   Innovent and Ollin entered a License for VEGF\/Ang2 Bispecific Antibody IBI324 (OLN324)\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/346.html\"><span class=\"screen-reader-text\">[Unannounced Deal]   Innovent and Ollin entered a License for VEGF\/Ang2 Bispecific Antibody IBI324 (OLN324)<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-346","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/346","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=346"}],"version-history":[{"count":2,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/346\/revisions"}],"predecessor-version":[{"id":349,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/346\/revisions\/349"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=346"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=346"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=346"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}